Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?

AJ Scheen - Expert Review of Clinical Pharmacology, 2023 - Taylor & Francis
Introduction Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two
major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective …
被引用次数：4 相关文章

Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?

AJ Scheen - Expert Review of Clinical Pharmacology, 2023 - europepmc.org
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective
antihyperglycemic agents underutilized? - Abstract - Europe PMC Sign in | Create an account …

Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?

A Scheen - Expert Review of Clinical Pharmacology, 2024 - orbi.uliege.be
INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF)
are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key …

Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?

AJ Scheen - Expert review of clinical pharmacology - pubmed.ncbi.nlm.nih.gov
Introduction Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two
major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective …